Transforming growth factor-beta in tegumentary leishmaniasis.
1. The course of infection with the protozoan parasite Leishmania is determined in part by its early replication in macrophages, the exclusive host cells for these organisms. Resistance to and recovery from leishmanial infection is related to cell-mediated immune responses in all forms of human and murine leishmaniasis. 2. Factors contributing to the early inhibition or proliferation of Leishmania are poorly understood, but cytokines such as IFN gamma, IL-10 or transforming growth factor beta (TGF-beta) are known to influence the replication of Leishmania in macrophages. 3. TGF-beta is a multipotential cytokine with diverse effects on cells of the immune system, including down-regulation of certain macrophage functions. Infection of murine or human macrophages by Leishmania induces the production of active TGF-beta. Recombinant TGF-beta added to murine or human macrophage cultures leads to increased intracellular replication of Leishmania. Exogenous TGF-beta administered in vivo promotes enhancement of infection, whereas its neutralization by monoclonal antibodies decreases the level of in vitro infection, and protects susceptible mice. 4. Susceptible animals treated with anti-TGF-beta monoclonal antibodies change their immune response, not increasing the expression of IL-4 while increasing the expression of IFN gamma mRNA in their draining lymph nodes. Resistant animals treated with TGF-beta also change their pattern of immune response as indicated by an increase of the important Th2 cytokine IL-10 mRNA in the draining lymph node. 5. TGF-beta has profound effects on the host response to Leishmania in both mouse and man, and probably is an important parasite escape mechanism.
Barral-Netto
M
M
Departamento de Anatomia Patológica, Faculdade de Medicina, Universidade Federal da Bahia, Brasil.
Barral
A
A
D000818:Animals; D000911:Antibodies, Monoclonal; D016207:Cytokines / Q000276:immunology; D006790:Host-Parasite Interactions; D006801:Humans; D007891:Leishmania / Q000187:drug effects / Q000254:growth & development; D016773:Leishmaniasis, Cutaneous / Q000276:immunology / Q000378:metabolism*; D008264:Macrophages / Q000276:immunology; D051379:Mice; D016212:Transforming Growth Factor beta / Q000276:immunology / Q000378:metabolism* / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D016207:Cytokines; D016212:Transforming Growth Factor beta